SRPT Q4 2020 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$145M+45.0% YoY

Gross Profit

$123M84.6% margin

Operating Income

-$171M-117.6% margin

Net Income

-$189M-130.4% margin

EPS (Diluted)

$-2.41

QoQ Revenue Growth

+0.8%

Cash Flow

Operating Cash Flow

-$175M

Free Cash Flow

-$203M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$3.0B

Total Liabilities

$2.2B

Stockholders' Equity

$762M

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$145M	$100M	+45.0%
Gross Profit	$123M	$85M	+45.2%
Operating Income	-$171M	-$230M	+25.8%
Net Income	-$189M	-$236M	+19.7%